Interview with Carl Johan Spak, new Member of the Board in Follicum

What is your background and what have you done before joining Follicum?

I have been in the pharmaceutical industry for more than 30 years. After some years in ACO and Pharmacia I joined Recip in 1995 when it started its business. With the exception of one year at Meda in 2008, I have been with Recip/Recipharm in many different positions. After several years heading Recipharm’s organisation for development services, I am since last year focussing on strategic investments for Recipharm, Follicum being one of the these. In my role as Senior Vice President for Strategic Investments & Projects I am looking for opportunities for investments where Recipharm can contribute with development and manufacturing services. In addition to my role at Recipharm I am engaged in several other biotech boards, in Sweden, UK, Israel and USA.

Why did you join Follicum as a Board Member?

I think that Follicum is a very interesting company with great opportunities having a unique platform and two exciting projects. My interest in joining the board of Follicum is of course also connected to the investment Recipharm has made in the newly made directed issue of shares.

What expertise will you bring to the Follicum Board?

I have a broad experience from the pharma industry ranging from development/manufacturing through marketing to business development and investments. I am at this stage of my working career more of a generalist than a specialist in a specific area. I have been part of starting a company like Recip/Recipharm but have also been part of starting new biotech companies, in the initial phase as CEO, like Prokarium Ltd and Empros Pharma AB. At the moment I am a director in several Life Science companies, both pharma and medtech and engaged in many different areas, e.g. oncology, diabetes, obesitas, antibiotics, emergency medicine and vaccines. I do believe that the board of a company like Follicum has a very important task in deciding the best strategy for the company and I am very much willing to take part in such strategic discussions.

For further information, please contact:

Jan Alenfall – CEO, Follicum AB
Telephone: +46 (0)46 - 19 21 97

Email: info@follicum.com

About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com 

Tags:

About Us

Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Aktietorget since 2014.

Subscribe

Documents & Links